Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; ext...

Related Keywords

Vienna ,Wien ,Austria ,Aljanae Reynolds ,Progeroid Laminopathies ,Sylvia Wheeler ,Bristol Myers Squibb ,Thomas Dietz ,Bluesphere Bio ,David Apelian ,Achillion Pharmaceuticals Inc ,Prnewswire Eiger Biopharmaceuticals Inc ,Schering Plough ,Regulatory Affairs ,Eiger Biopharmaceuticals Inc ,Nasdaq ,Chief Executive Officer ,Chief Operating Officer ,Post Bariatric Hypoglycemia ,Breakthrough Therapy ,Pediatric Disease ,Processing Deficient Progeroid ,Based Regimens ,Executive Medical Officer ,Senior Clinical Advisor ,Executive Vice President ,Chief Medical Officer ,Achillion Pharmaceuticals ,Private Securities Litigation Reform Act ,Quarterly Report ,